MA46355A - Procédé de traitement du carcinome urothélial et d'autres malignités génito-urinaires à l'aide de n-(4-(6,7-diméthoxyquinolin-4-yloxy)-phényl)-n'-(4-fluorophényl)cyclopropane -1,1-dicarboxamide - Google Patents
Procédé de traitement du carcinome urothélial et d'autres malignités génito-urinaires à l'aide de n-(4-(6,7-diméthoxyquinolin-4-yloxy)-phényl)-n'-(4-fluorophényl)cyclopropane -1,1-dicarboxamideInfo
- Publication number
- MA46355A MA46355A MA046355A MA46355A MA46355A MA 46355 A MA46355 A MA 46355A MA 046355 A MA046355 A MA 046355A MA 46355 A MA46355 A MA 46355A MA 46355 A MA46355 A MA 46355A
- Authority
- MA
- Morocco
- Prior art keywords
- malignities
- dimethoxyquinolin
- dicarboxamide
- genitourinary
- cyclopropane
- Prior art date
Links
- -1 4- (6,7-DIMETHOXYQUINOLIN-4-YLOXY) -PHENYL Chemical class 0.000 title 1
- 206010044412 transitional cell carcinoma Diseases 0.000 title 1
- 208000023747 urothelial carcinoma Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/868—Vaccine for a specifically defined cancer kidney
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/884—Vaccine for a specifically defined cancer prostate
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662400481P | 2016-09-27 | 2016-09-27 | |
US201762457952P | 2017-02-12 | 2017-02-12 | |
US201762459340P | 2017-02-15 | 2017-02-15 | |
US201762552296P | 2017-08-30 | 2017-08-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA46355A true MA46355A (fr) | 2019-08-07 |
Family
ID=60190916
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA046355A MA46355A (fr) | 2016-09-27 | 2017-09-27 | Procédé de traitement du carcinome urothélial et d'autres malignités génito-urinaires à l'aide de n-(4-(6,7-diméthoxyquinolin-4-yloxy)-phényl)-n'-(4-fluorophényl)cyclopropane -1,1-dicarboxamide |
Country Status (7)
Country | Link |
---|---|
US (2) | US20210275515A1 (fr) |
EP (1) | EP3518928A1 (fr) |
JP (1) | JP2019529476A (fr) |
AU (1) | AU2017336547A1 (fr) |
CA (1) | CA3038500A1 (fr) |
MA (1) | MA46355A (fr) |
WO (1) | WO2018064191A1 (fr) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3589754B1 (fr) | 2017-03-01 | 2023-06-28 | F. Hoffmann-La Roche AG | Procédés diagnostiques et thérapeutiques relatifs au cancer |
WO2019148044A1 (fr) | 2018-01-26 | 2019-08-01 | Exelixis, Inc. | Composés destinés au traitement de troubles dépendant de la kinase |
CN116808044A (zh) | 2018-06-15 | 2023-09-29 | 汉达癌症医药责任有限公司 | 激酶抑制剂的盐类及其组合物 |
CN113196061A (zh) * | 2018-10-18 | 2021-07-30 | 豪夫迈·罗氏有限公司 | 肉瘤样肾癌的诊断和治疗方法 |
EP4188376A1 (fr) * | 2020-07-31 | 2023-06-07 | Exelixis, Inc. | Associations pour le traitement du cancer |
US11590122B2 (en) | 2021-02-19 | 2023-02-28 | Slayback Pharma Llc | Pharmaceutical compositions of cabozantinib |
US20220280500A1 (en) * | 2021-02-19 | 2022-09-08 | Slayback Pharma Llc | Pharmaceutical compositions of cabozantinib |
US20220387418A1 (en) * | 2021-02-19 | 2022-12-08 | Slayback Pharma Llc | Pharmaceutical compositions of cabozantinib |
US20220362235A1 (en) * | 2021-02-19 | 2022-11-17 | Slayback Pharma Llc | Pharmaceutical compositions of cabozantinib |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE517091T1 (de) | 2003-09-26 | 2011-08-15 | Exelixis Inc | C-met-modulatoren und verwendungsverfahren |
WO2008083319A1 (fr) | 2006-12-29 | 2008-07-10 | Il Yang Pharmaceutical Company, Ltd. | Formes à l'état solide de l'ilaprazole de pureté énantiomérique |
EP4014971A1 (fr) | 2010-07-16 | 2022-06-22 | Exelixis, Inc. | Compositions pharmaceutiques modulatrices de c-met |
BR112013020362A2 (pt) | 2011-02-10 | 2018-05-29 | Exelixis Inc | processos para a preparação de compostos de quinolina, compostos e combinações farmacêuticas que os contem |
-
2017
- 2017-09-27 CA CA3038500A patent/CA3038500A1/fr not_active Abandoned
- 2017-09-27 WO PCT/US2017/053766 patent/WO2018064191A1/fr unknown
- 2017-09-27 US US16/336,724 patent/US20210275515A1/en not_active Abandoned
- 2017-09-27 AU AU2017336547A patent/AU2017336547A1/en not_active Abandoned
- 2017-09-27 MA MA046355A patent/MA46355A/fr unknown
- 2017-09-27 JP JP2019516536A patent/JP2019529476A/ja not_active Withdrawn
- 2017-09-27 EP EP17791484.3A patent/EP3518928A1/fr not_active Withdrawn
-
2022
- 2022-11-29 US US18/059,840 patent/US20230130243A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CA3038500A1 (fr) | 2018-04-05 |
US20210275515A1 (en) | 2021-09-09 |
JP2019529476A (ja) | 2019-10-17 |
AU2017336547A1 (en) | 2019-05-02 |
WO2018064191A1 (fr) | 2018-04-05 |
US20230130243A1 (en) | 2023-04-27 |
EP3518928A1 (fr) | 2019-08-07 |
WO2018064191A8 (fr) | 2019-04-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA46355A (fr) | Procédé de traitement du carcinome urothélial et d'autres malignités génito-urinaires à l'aide de n-(4-(6,7-diméthoxyquinolin-4-yloxy)-phényl)-n'-(4-fluorophényl)cyclopropane -1,1-dicarboxamide | |
MA42819A (fr) | Procédés pour le traitement d'infections virales à arenaviridae et coronaviridae | |
DK3472183T5 (da) | Variant adeno-associerede virus og fremgangsmåder til anvendelse | |
DK3426781T3 (da) | Mikro-rna'er og fremgangsmåder til anvendelse deraf | |
DK3445388T3 (da) | Materialer og fremgangsmåder til behandling af hæmoglobinopatier | |
DK3445773T3 (da) | Adeno-associerede virusvariantcapsider og fremgangsmåder til anvendelse deraf | |
IL256805B (en) | Compounds -4-)-n aryl(phenyl)-2-(4-(1,1-(difluoroalkyl(phenyl)-acetamide and their use for the treatment of diseases modulated by rorgt | |
DK3858977T5 (da) | Stamme til forebyggelse og behandling af stofskiftesygdomme, og brugen heraf | |
DK3277815T3 (da) | Oligonukleotidforbindelser til behandling af præeklampsi og andre angiogene lidelser | |
BR112016018450A2 (pt) | formas sólidas cristalinas de n-{4-[(6,7-dimetoxiquinolin-4-il)oxi]fenil}-n'-(4-fluorofenil)ciclopropano-1,1-dicarboxamida, processos de preparo e métodos de uso | |
DK3402499T3 (da) | Sammensætninger og fremgangsmåder til behandlingen af type 1 diabetes | |
MA44672A (fr) | Procédé de traitement du cancer à cellules rénales à l'aide de n-(4-(6,7-diméthoxyquinolin-4-yloxy) phényl)-n'-(4-fluorophény)cyclopropane-1,1-dicarboxamide, (2s)-hydroxybutanedioate | |
DK3325444T3 (da) | Fremgangsmåder til fremstilling af n-(4-fluorbenzyl)-n-(1-methylpiperidin-4-yl)-n'-(4-(2-methylpropyloxy)phenylmethyl)carbamid og dets tartratsalt og polymorf form c | |
DK3262037T3 (da) | Nyt quinolinderivat til anvendelse til behandling og forebyggelse af virusinfektioner | |
DK3557998T3 (da) | Sammensætninger, kompositioner og anvendelsesmetoder | |
DK3119797T3 (da) | Raav-baserede sammensætninger og fremgangsmåder til behandling af amyotrofisk lateralsklerose | |
MA44681A (fr) | Administration de b-sarcoglycane et de microarn-29 à l'aide d'un vecteur de virus adéno-associé, et traitement de la dystrophie musculaire | |
DK3405215T3 (da) | Fremgangsmåder til behandling af danon-sygdom og andre autofagilidelser | |
JP2018172409A5 (ja) | 15−hepeを含む組成物および同組成物を使用する方法 | |
DK3789501T3 (da) | Fremgangsmåde til diagnosticering, behandling og forebyggelse af parkinsons sygdom | |
DK3240538T3 (da) | Anvendelse af masitinib til behandling af en underpopulation af patienter med amyotrofisk lateralsklerose | |
MA41120A (fr) | Compositions comprenant le 15-hepe et méthodes de traitement ou de prévention de la fibrose à l'aide de celles-ci | |
EP3551612A4 (fr) | Procédé de préparation de n-(4-(6,7-diméthoxyquinolin-4-yloxy) phényl)-n'-(4-fluorophényl)cyclopropane-1, 1-dicarboxamide, (2s)-hydroxybutanedioate et ses polymorphes | |
DK3744316T3 (da) | Oftalmisk farmaceutisk sammensætning, fremgangsmåde til fremstilling deraf og anvendelse deraf | |
MA45226A (fr) | Compositions et méthodes de traitement ou de prévention d'affections liées à l'oxalate |